Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events-Reference-Cited by-同舟云学术

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events

Published:2012-05 Issue:5 Volume:8 Page:630-638
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Schmidt Claudia,Smith Carol,Barin Burc,Bakhtyari Arash,Bart Pierre-Alexandre,Bekker Linda-Gail,Chomba Elwyn,Clumeck Nathan,Ho David,Hoosen Anwar,Jaoko Walter,Kaleebu Pontiano,Karita Etienne,Keefer Michael C,van Lunzen Jan,McMichael Andrew,Mehendale Sanjay,Peters Barry,Ramanathan Vadakkuppatu D.,Robinson Andrew,Rockstroh Juergen,Vardas Eftyhia,Vets Eva,Weber Jonathan,Graham Barney S.,Than Soe,Excler Jean-Louis,Kochhar Sonali,Ho Martin,Heald Alison,Fast Patricia E.

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/hv.19454

Reference15 articles.

1. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

2. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity

3. Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

4. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa

5. Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety and vaccine-induced seropositivity in healthy volunteers from HIV vaccine trials;AIDS;2019-11-01

2. Social and Behavioral Consequences of Participation in HIV Preventive Vaccine Trials in the ANRS COHVAC Cohort;JAIDS Journal of Acquired Immune Deficiency Syndromes;2018-10-01

3. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa;Human Vaccines & Immunotherapeutics;2013-12-27

4. Novel directions in HIV-1 vaccines revealed from clinical trials;Current Opinion in HIV and AIDS;2013-09